Eib shares amazing, true stories of those who have been through cancer and discovers that when God and cancer meet, hope is never far away. This book is packed with a daily dose of encouragement.

It is an essential read for anyone on this difficult journey.

Cancer touches nearly everyone, whether firsthand or through the life of a loved one. Counselor and teacher Yvonne Ortega discovered this when she was diagnosed with breast cancer and began her journey to recovery. In Hope for the Journey through Cancer, she shares with readers her personal triumphs and setbacks with humor and refreshing candor, always reminding us of God's desire to meet us exactly where we are. These sixty devotions are divided into sections--diagnosis, surgery, treatment, and recovery--each incorporating Scripture into daily life. Ortega's attention to even the most basic hopes and fears that a cancer patient faces each day offers encouragement that can come only from one who has been there herself.

This compassionate book presents dialectical behavior therapy (DBT), a proven psychological intervention that Marsha M. Linehan developed specifically for the impossible situations of life--and which she and Elizabeth Cohn Stuntz now apply to the unique challenges of cancer for the first time. *How can you face the fear, sadness, and anger without being paralyzed by them? *Is it possible to hold on to hope without being in denial? *How can you nurture supportive relationships when you have barely enough energy to take care of yourself? Learn powerful DBT skills that can help you make difficult treatment decisions, manage overwhelming emotions, speak up for your needs, and tolerate distress. The stories and collective wisdom of other cancer patients and survivors illustrate the coping skills and show how you can live meaningfully, even during the darkest days.

In the late 1980s, a promising new treatment for breast cancer emerged: high-dose chemotherapy with autologous bone marrow transplantation or HDC/ABMT. By the 1990s, it had burst upon the oncology scene and disseminated rapidly before having been carefully evaluated. By the time published studies showed that the procedure was ineffective, more than 30,000 women had received the treatment, shortening their lives and adding to their suffering. This book tells of the rise and demise of HDC/ABMT for metastatic and early stage breast cancer, and fully explores the story's implications, which go well beyond the immediate procedure, and beyond breast cancer, to how we in the United States evaluate other medical procedures, especially life-saving ones. It details how the factors that drove clinical use--patient demand, physician enthusiasm, media reporting, litigation, economic exploitation, and legislative and administrative mandates--converged to propel the procedure forward despite a lack of proven clinical effectiveness. It also analyzes the limited effect of technology assessments before randomized clinical trials evaluated decisively the procedure and the ramifications of this system on healthcare today. Sections of the book consider the initial conditions surrounding the emergence of the new breast cancer treatment, the drivers of clinical use, and the struggle for evidence-based medicine. A concluding section considers the significance of the story for our healthcare system.